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Summary 
Patients with porphyria cutanea tarda (PCT) reveal a susceptibility to reversible inactivation of hepatic 
uroporphyrinogen decarboxylase, which might be triggered by alcohol, hepatitis C virus infection, and iron overload. 
Inherited factors that may predispose to clinically overt PCT also include sequence deviations in the HFE gene that is 
mutated in classical hemochromatosis. Here, we studied the prevalence of both common and rare hemochromatosis 
gene variations in 51 PCT patients and 54 healthy controls of German origin. The frequency of the common HFE gene 
mutation C282Y was 15.7 % in PCT patients and 2.8 % in healthy control individuals (P < 0.001). By contrast, the 
frequencies of the common H63D mutation did not differ, and the allele frequencies of the less frequently observed 
sequence deviations as substitution S65C in the HFE gene and mutation Y250X in the TFR2 gene underlying 
hemochromatosis type 3 (HFE3) were < 0.02 both in PCT patients and controls. Our results comprise the first 
molecular studies of both common and rare hemochromatosis gene variants in German PCT patients, indicating a 
significant role of the C282Y mutation in the pathogenesis of PCT. 
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Introduction 
 
 The porphyrias are clinically and genetically 
heterogeneous metabolic diseases arising from 
predominantly inherited catalytic deficiencies of specific 
enzymes involved in heme biosynthesis. Porphyria 
cutanea tarda (PCT) (OMIM 176100), the most frequent 
type of porphyria worldwide, results from a decreased 
catalytic activity of uroporphyrinogen decarboxylase 
(UROD), the fifth enzyme in heme biosynthesis (Bickers 
et al. 2003). 
 The disorder represents the only type of 
porphyria that is not exclusively inherited 
monogenetically and at least two different types can be 
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distinguished: acquired/sporadic (type I) PCT, in which 
the enzymatic deficiency is limited to the liver and 
inherited/familial (type II) PCT, which is inherited as an 
autosomal dominant trait with a decrease of enzymatic 
activity in all tissues (De Verneuil et al. 1978, Grossman 
et al. 1979). Currently, the ratio between type I and type 
II PCT is estimated to be approximately 3:1 to 4:1, 
although recent data suggest that, in some countries, the 
frequency of type II PCT might be much higher than 
previously thought (Bickers et al. 2003, De Verneuil et 
al. 1978, Poblete-Gutierrez et al. 2004). 
 The diagnosis of PCT is made on the basis of 
cutaneous manifestations, a characteristic urinary 
porphyrin excretion profile, and, in some laboratories, by 
measuring UROD activities in red blood cells. The skin 
findings include increased photosensitivity due to 
photosensitization by porphyrins and skin fragility as 
well as blistering, erosions, crusts, and miliae on the sun-
exposed areas of the body (Fig. 1). Additionally, 
hyperpigmentation, hypertrichosis, sclerodermoid 
plaques, and scarring alopecia can be observed. 
Biochemically, an increased excretion of uroporphyrin 
(type I isomers > type III isomers), 7-carboxyl porphyrins 
(type III isomers > type I isomers), and coproporphyrin in 
the urine can be found. Enzymatically, UROD activity is 
decreased by approximately 50 % in red blood cells of 
individuals suffering from type II PCT (Bickers et al. 
2003, De Verneuil et al. 1978, Grossman et al. 1979). 
 A wide range of triggering factors has been 
reported to precipitate the clinical manifestation of PCT, 
among them alcohol, estrogens, polychlorinated 
hydrocarbons, hemodialysis in patients with renal failure, 
viral infections such as hepatitis C and HIV, hepatic iron, 
and the inheritance of specific mutations in the HFE gene 
underlying classic hemochromatosis. Interestingly, 
homozygosity for the HFE gene mutation C282Y was 
found to be associated with an earlier onset of cutaneous 
lesions in both sporadic and familial PCT, the effect 
being more marked in familial PCT (Brady et al. 2000). 
 Histopathologically, 60 - 70 % of those 
individuals affected by PCT will develop hepatic 
siderosis (Uys and Eales 1963, Elder and Worwood 
1998). Clinical and experimental studies suggest that 
UROD is reversibly inhibited by high iron concentrations 
(Sampietro et al. 1999). This is consistent with the 
observation that phlebotomy can lead to clinical 
remission and reversal of the metabolic defect (Lundvall 
and Weinfeld 1968, Sampietro et al. 1998). Several 
groups have studied the common HFE gene sequence 
deviations C282Y and H63D, providing evidence for 
increased frequencies of these molecular alterations in 
PCT patients from distinct ethnic origin (Hift et al. 1997, 
Roberts et al. 1997a, b, Santos et al. 1997, Stuart et al. 
1998, Bonkovsky et al. 1998, Bulaj et al. 2000, 
Tannapfel et al. 2001, Furuyama et al. 1999). 
 
 
 
Fig. 1. Blisters and erosions on the fingers and the back of both hands in an individual suffering from overt PCT. 
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 Recently though, another mutation in the HFE 
gene, designated S65C, was shown to be associated with 
a mild form of iron overload (Mura et al. 1999), as 
indicated by significantly higher mean serum transferrin 
saturation in S65C heterozygotes (Beutler et al. 1999, 
2000). In addition, a further novel mutation, designated 
Y250X, in the TFR2 gene, encoding the transferrin 
receptor 2, was detected in a subgroup of 
hemochromatosis patients suffering from 
hemochromatosis type 3 (Camaschella et al. 2000). 
 To date, the occurrence of mutation S65C has 
only been reported in two PCT patients (Barton et al. 
1999, von Ahsen et al. 2001), whereas the frequency of 
mutation Y250X in the TFR2 gene has not been defined 
in PCT. Therefore, we herein sought to delineate the 
incidence of common and rare hemochromatosis 
mutations in PCT patients from Germany. 
 
 
 
Fig. 2. Molecular analysis of the H63D, C282Y, and S65C HFE 
gene polymorphisms. (A) The derivative melting curves of the 
following genotypes are shown: C282/C282/H63/H63 (green), 
C282/Y282/H63/D63 (red), Y282/Y282/H63/H63 (black), 
C282/C282/D63/D63 (pink). (B) The derivative melting curves of 
the following genotypes are shown: H63/H63/S65/S65 (dark 
green), H63/D63/S65/S65 (blue), H63/H63/S65/C65 (grey). 
Negative controls (water) without DNA were run in parallel. The 
values for the respective melting temperatures varied for +/- 2.0 
oC between different experiments. 
 
Methods 
 
Patients  
 Diagnosis of PCT was established on the basis 
of cutaneous photosensitivity and typical skin symptoms 
on the sun exposed areas like hands, forearms and face in 
combination with a characteristic porphyrin excretion 
profile in the urine consisting of increased values for 
urinary uroporphyrin (ten times higher than the upper 
normal range, type I isomers > type III isomers), 7-
carboxyl porphyrins (type III isomers > type I isomers), 
and coproporphyrin. Urine levels of the porphyrin 
precursors δ-aminolevulinic acid and porphobilinogen 
were within normal ranges. Hemochromatosis genotypes 
were analyzed in 51 German PCT patients diagnosed and 
registered in the Porphyria Center Aachen, Germany, the 
majority of them residing in the federal state of North-
Rhine-Westphalia. For control purposes, we analyzed 54 
healthy individuals without porphyria residing in the 
same geographical region for the occurrence of these 
mutations. Blood samples were collected in tubes 
containing ethylenediamine tetraacetic acid (EDTA). All 
individuals provided informed consent for inclusion in 
the investigation. 
 
Genotyping 
 Genomic DNA was isolated from EDTA-
anticoagulated whole blood using a standard technique 
(QIAamp DNA Blood Kit, Qiagen, Hilden, Germany). 
For detection of the C282Y and H63D polymorphisms in 
the HFE gene, we employed LightCycler technology 
(Roche, Mannheim, Germany) essentially as described 
previously (Mangasser-Stephan et al. 1999, Tag et al. 
2001), resulting in the genotype specific melting curves 
(Fig. 2A).  
 Likewise, the S65C mutation was detected by 
melting point analysis with fluorescent hybridization 
probes using the HFE H63D+S65C ToolSet for 
LightCycler (Genes-4U, Neftenbach, Switzerland). The 
assay allowed simultaneous detection of mutations H63D 
and S65C in the HFE gene by their typical melting 
temperatures (Tm) (Bollhalder et al. 1999) (Fig. 2B).  
 For genotyping of mutation Y250X mutation in 
the TFR2 gene, we employed direct sequencing. Primers 
for PCR amplification were 5´-CCC TAC AGC GCC 
ATC GGC-3´ and 5´-GGC CCA CTG GAT CCA CGC-
3´ (Bulaj et al. 2000). For cycle sequencing, DNA (50 ng) 
was amplified together with 4 μl Terminator Ready 
Reaction Mix (Applied Biosystems, Weiterstadt, 
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Germany) and 0.5 mmol primer in a total reaction volume 
of 20 μl for 25 cycles (96 °C/20 sec, 50 °C/20 sec, 
60 °C/4 min). Products were precipitated, dissolved in 24 
μl Template Suppression Reagent (Applied Biosystems), 
and denatured at 95 °C for 2 min. Capillary 
electrophoresis and data analysis were performed on the 
ABI PRISM 310 automated sequencer (Applied 
Biosystems). 
 
Statistics  
 As tests for association, we compared the 
distribution of alleles and genotypes in contingency tables 
by Pearson's goodness-of-fit χ2 test and Armitage's trend 
test, respectively, using software developed by T. 
Wienker and T. Strom (http://ihg.gsf.de/). Consistency of 
genotype frequencies with Hardy-Weinberg equilibrium 
was confirmed using an exact test. 
 
 
Table 1. Allele and genotype frequencies of common HFE gene mutations in 51 PCT patients and 54 controls 
 
 Mutation a PCT  Controls Tests for association 
 H63D C282Y Number 
(frequency) 
Number 
(frequency) 
Contingency table 
statistics 
187 C 80 (0.78)  88 (0.81) 
187 G 
 
22 (0.22)  20 (0.19) 
 
P = 0.581 
845 G 86 (0.84) 105 (0.97) 
Alleles 
 
845 A 16 (0.16)    3 (0.03) 
 
OR = 6.5, 95 % CI = 
1.8 - 23.1, P = 0.001 
187 CC 845 GG 20 (0.39) 34 (0.63) 
187 CC 845 GA   7 (0.14)   2 (0.04) 
187 CC 845 AA   4 (0.08)   0 (0.00) 
187 CG 845 GG 17 (0.33) 15 (0.28) 
187 CG 845 GA   1 (0.02)   1 (0.02) 
187 GG 845 GG   2 (0.04)   2 (0.04) 
 
187 CC  31 (0.61) 36 (0.67) 
187 CG 18 (0.35) 16 (0.30) 
187 GG 
 
  2 (0.04)   2 (0.04) 
 
 
P = 0.578 
845 GG 39 (0.76) 51 (0.94) 
845 GA   8 (0.16)   3 (0.06) 
Genotypes b 
 
845 AA   4 (0.08)   0 (0.00) 
 
 
OR = 11.7, P = 0.005 
(Armitage's trend test) 
 
 
a cDNA nucleotide variant c.187C→G corresponds to amino acid substitution H63D and c.845G→A corresponds to C282Y. 
b Genotype combinations not listed were not observed. 
 
 
Results 
 
PCT patients 
 Of the 51 PCT patients studied, 8 (15.7 %) were 
heterozygous for mutation C282Y in the HFE gene and 4 
(7.8 %) were homozygous for this mutation (Table 1). 
Eighteen patients (35.3 %) were heterozygous for the 
H63D mutation and 2 (3.9 %) were homozygous carriers 
of this mutation. One patient was a compound 
heterozygote (C282Y/H63D). 
 A single PCT patient carried mutation S65C in 
the heterozygous state, but neither mutation C282Y nor 
H63D. Automated sequencing revealed that none of the 
PCT patients carried mutation Y250X in the TFR2 gene. 
 
Control individuals 
 Of the 54 healthy control individuals, 3 (5.6 %) 
were heterozygous for mutation C282Y, 16 (29.6 %) 
were heterozygous for H63D (1 compound heterozygote), 
and 2 (3.7 %) were homozygous for the latter mutation. 
One of the controls was shown to be heterozygous for 
mutation S65C in the HFE gene, and another control 
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carried mutation Y250X in the TFR2 gene in the 
heterozygous state. 
 
Statistical analysis 
 All genotypes were in Hardy-Weinberg 
equilibrium, except for the C282Y mutation in PCT 
patients (P < 0.05). 
 Accordingly, C282Y allele frequencies were 
significantly higher in PCT patients compared to controls 
(OR 6.5, 95 % CI 1.8 - 23.1, P < 0.01, Table 1). 
Homozygous C282Y genotypes increased the PCT risk 
significantly (OR 5.2, 95 % CI 1.3 - 19.8, P < 0.05). As 
determined by Armitages's trend test, the common odds 
ratio of the C282Y mutation was 11.7 (P < 0.01). 
 Allele and genotype frequencies of the H63D, 
S65C, or Y250X mutations did not differ significantly 
between PCT patients and control individual. 
 
Discussion 
 
 The aim of this study was to assess the 
frequency of common and rare genetic alterations in the 
HFE and TFR2 genes in association with PCT in German 
patients suffering from this disorder rather than 
evaluating the relative importance of these factors in 
disease pathogenesis or determining disease-specific 
mechanisms contributing to overt disease. Therefore, we 
studied the occurrence of specific sequence deviations 
that have all been previously reported to be associated 
with hemochromatosis and disturbance of iron 
metabolism, as PCT is an iron-dependent disease and up 
to 65 % of patients with PCT show an increase in total 
body iron stores as well as hepatic iron concentrations 
(Lundvall et al. 1970, Edwards et al. 1989, Fargion et al. 
1996). 
 In several previous reports the association of 
common HFE gene mutations with PCT has been 
studied, indicating that major differences exist between 
allele frequencies and distributions of these sequence 
variants when comparing patients from different 
geographical background within Europe. Whereas C282Y 
was detected with relatively high frequencies in PCT 
patients from Germany, France, Hungary, Southern Italy, 
the Netherlands, Spain, and the United Kingdom (Roberts 
et al. 1997a, Santos et al. 1997, Tannapfel et al. 2001, 
Stölzel et al. 2003, Feder et al. 1996, D’Amato et al. 
1998, Enriquez de Salamanca et al. 1999, Nagy et al. 
2004, Chiaverini et al. 2003), a single investigation from 
Northern Italy revealed that the occurrence rate of this 
mutation showed no differences when comparing patients 
suffering from PCT and healthy control individuals, 
whereas the frequency of H63D was significantly 
increased (Sampietro et al. 1998). Taking these data into 
consideration, particularly the previous studies performed 
on German PCT patients (Tannapfel et al. 2001, Stölzel 
et al. 2003), the high frequency of the C282Y HFE gene 
alleles observed in our and previous investigations in 
German PCT patients strongly suggest that this mutation 
is associated with the manifestation of overt disease in 
PCT, thus emphasizing that liver iron content is an 
important pathogenic factor in this disease. Apparently, 
the penetrance of mutation C282Y is much stronger than 
that of H63D, as reflected by the fact that individuals 
carrying genotype C282Y/C282Y are at much higher risk 
for iron overload than those with genotypes 
C282Y/H63D or H63D/H63D (Egger et al. 2002, The 
UK Haemochromatosis Consortium 1997, Moirand et al. 
1999). 
 Beside the avoidance of well known triggering 
factors such as alcohol and estrogens, two major 
therapeutic regimens for PCT have been described: 
phlebotomy and low-dose chloroquine therapy. 
Phlebotomy leads to resolution of skin fragility and 
blistering within 2 - 4 months. However, normalization of 
urinary porphyrin concentrations usually takes longer 
(about 12 months). Chloroquine is thought to work by 
accelerating the secretion of porphyrins and may also 
inhibit porphyrin synthesis. The standard therapy consists 
of 125 mg chloroquine twice weekly, and complete 
remission can be expected within 6 – 9 months. 
Chloroquine and phlebotomy can also be used in 
combination in order to induce remission faster (Bickers 
et al. 2003, Lecha et al. 2003). 
 Of note, however, a recent report indicates that 
the genetic background of PCT patients with regard to the 
presence of the common HFE gene mutations C282Y and 
H63D might play a critical role in the outcome of 
chloroquine treatment. Whereas heterozygosity for 
mutation C282Y and compound heterozygosity for 
C282Y and H63D did not compromise the therapeutic 
response to chloroquine, PCT patients homozygous for 
C282Y seemed to retain high serum ferritin and 
transferrin saturation and, most importantly, failed to 
respond to chloroquine therapy (Stölzel et al. 2003). 
 In contrast to the two common HFE gene 
mutations C282Y and H63D, very little is known to date 
about the association of other mutations causing 
hemochromatosis and PCT. Our data indicate that the 
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overall prevalence rate of mutation S65C in the HFE 
gene within the German PCT population studied herein is 
2.0 %, consistent with the results of previous studies 
performed in Denmark (Simonsen et al. 1999), France 
(Chiaverini et al. 2003), and the United States (Mura et 
al. 1999, Beutler et al. 1999), in which the prevalence 
ranged from 1.5 to 2.5 %. These numbers indicate that 
this sequence deviation does not play a crucial role in the 
pathogenesis of PCT, a notion that is further supported by 
a similar study on 47 PCT patients from Bulgaria who 
likewise did not display an increased frequency of 
mutation S65C when compared to healthy control 
individuals (Ivanova et al. 1999). 
 In a recent study, Lamoril and colleagues sought 
to evaluate a possible association between type I PCT and 
five different single nucleotide polymorphisms (SNPs) in 
the human transferrin receptor (TFRC) gene. Independent 
of HFE gene mutations C282Y, H63D, and S65C they 
reported an association between the IVS4+198T-allele in 
the TFRC gene and sporadic PCT, suggesting that type I 
PCT has to be considered as a multi-factorial (complex) 
disease, in which not only alterations in the HFE gene 
might confer susceptibility to iron overload but also other 
gene variants known to influence intracellular iron 
metabolism (Lamoril et al. 2002). 
 Based on these observations we searched for a 
putative association between PCT and a mutation in the 
TFR2 gene, encoding the transferrin receptor 2, that has 
been recently described in patients with hemochromatosis 
type 3 (Camaschella et al. 2000). This sequence variation 
occurs in exon 6 of TFR2 and consists of a C-to-G 
transversion at nucleotide position 750 of the TFR2 
cDNA, and results in the substitution of a tyrosine residue 
by a premature termination codon (Y250X). TFR2 binds 
transferrin, plays a critical role in cellular uptake of 
transferrin-bound iron in the liver, and is not down-
regulated in the setting of iron overload (Kawabata et al. 
1999, Fleming et al. 2000). The results of our molecular 
genetic studies revealed that none of the German PCT 
patients studied herein carried mutation Y250X in the 
TFR2 gene, making an association between PCT and 
alterations in the transferrin receptor 2 unlikely. 
 In conclusion, our study in a subset of German 
patients suffering from PCT confirms the association 
between the common HFE mutation C282Y and PCT, 
and does not support a link between this disorder of heme 
biosynthesis and the rare HFE gene mutation S65C or 
mutation Y250X in the TFR2 gene. The complex 
pathomechanisms affecting the activity of UROD and 
causing overt disease still remain to be defined in more 
detail in future studies, particularly the putative 
contribution of as yet unknown mutations in the HFE 
gene or in other genes involved in iron metabolism, 
which might promote accumulation of iron and toxic iron 
species, thereby contributing to inactivation of UROD. 
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